recent
emerg
sever
acut
respiratori
syndrom
sar
caus
novel
coronaviru
sarscov
spread
rapidli
mani
countri
develop
sar
vaccin
urgent
requir
order
studi
immunogen
uvinactiv
purifi
sarscov
virion
vaccin
candid
subcutan
immun
mice
uvinactiv
sarscov
without
adjuv
chose
aluminum
hydroxid
gel
alum
adjuv
long
safeti
histori
human
use
observ
uvinactiv
sarscov
virion
elicit
high
level
humor
immun
result
gener
longterm
antibodi
secret
memori
b
cell
addit
alum
vaccin
formula
serum
igg
product
augment
reach
level
similar
found
hyperimmun
mice
though
still
insuffici
elicit
serum
iga
antibodi
notabl
sarscov
virion
abl
induc
longterm
antibodi
product
even
without
adjuv
antisarscov
antibodi
elicit
mice
recogn
spike
nucleocapsid
protein
viru
abl
neutral
viru
furthermor
uvinactiv
virion
induc
region
lymph
node
tcell
prolifer
signific
level
cytokin
product
ifnc
tnfa
upon
restimul
inactiv
sarscov
virion
vitro
thu
whole
kill
virion
could
serv
candid
antigen
sar
vaccin
elicit
humor
cellular
immun
new
diseas
call
sever
acut
respiratori
syndrom
sar
origin
china
late
spread
rapidli
mani
countri
upon
outbreak
global
collabor
network
coordin
result
unpreced
intern
effort
novel
type
coronaviru
sarscov
identifi
etiolog
agent
sar
march
genom
sequenc
sarscov
complet
know
sarscov
featur
characterist
coronavirus
quit
differ
previous
known
coronavirus
group
iiii
repres
new
group
group
iv
assum
sarscov
mutant
coronaviru
transmit
wild
anim
develop
abil
product
infect
human
genom
sarscov
singlestrand
plussens
kb
length
contain
five
major
open
read
frame
encod
nonstructur
replicas
polyprotein
structur
protein
spike
envelop
e
membran
nucleocapsid
protein
n
order
approxim
size
coronavirus
reason
sarscov
induc
sever
respiratori
distress
infect
individu
still
unclear
patient
sar
probabl
sar
case
viru
detect
sputum
stool
plasma
rtpcr
patient
develop
serum
antibodi
sarscov
high
antibodi
titer
n
protein
maintain
month
infect
gener
poor
pathogen
difficulti
propag
vitro
studi
regard
immun
human
coronavirus
veterinari
field
howev
coronavirus
known
mani
year
caus
varieti
lung
liver
gut
diseas
anim
learn
anim
model
humor
cellular
immun
respons
may
contribut
protect
coronaviru
diseas
includ
sar
review
see
clinic
manifest
sar
hardli
distinct
common
respiratori
viral
infect
includ
influenza
influenza
epidem
may
occur
simultan
reemerg
sar
urgent
requir
develop
effect
sar
vaccin
well
sensit
diagnost
test
specif
sar
recent
angiotensinconvert
enzym
identifi
cellular
receptor
sarscov
first
step
viral
infect
presum
bind
protein
receptor
murin
mhv
model
protein
known
contain
import
virusneutr
epitop
elicit
neutral
antibodi
mice
therefor
protein
would
first
candid
coronaviru
protein
induct
immun
howev
n
protein
also
known
contribut
gener
host
immun
respons
follow
establish
vaccin
protocol
one
best
way
shorten
time
cost
new
vaccin
develop
current
avail
vaccin
human
inactiv
appli
cutan
except
oral
polio
vaccin
adjuv
usag
mostli
limit
aluminum
hydroxid
gel
alum
order
know
immunogen
inactiv
sarscov
vaccin
candid
immun
mice
uvinactiv
sarscov
either
without
alum
report
evalu
humor
cellular
immun
elicit
uvinactiv
sarscov
administ
subcutan
sarscov
kindli
suppli
dr
jsm
peiri
depart
microbiolog
univers
hong
kong
viru
amplifi
vero
cell
purifi
sucros
densiti
gradient
centrifug
concentr
viru
expos
uv
light
jcm
order
inactiv
viru
confirm
viru
complet
lost
infect
method
femal
balbc
mice
purchas
nippon
slc
inc
shizuoka
japan
hous
specif
pathogenfre
condit
experiment
procedur
carri
niidrecommend
guidelin
mice
subcutan
inject
via
back
right
left
hind
leg
footpad
lg
uvinactiv
purifi
sarscov
without
mg
alum
boost
procedur
week
prime
blood
obtain
tail
vein
allow
clot
overnight
sera
collect
centrifug
elisa
microtit
plate
dynatech
chantili
va
coat
overnight
sarscovinfect
mockinfect
vero
cell
lysat
treat
follow
uvinactiv
detect
n
protein
plate
coat
lysat
chick
embryo
fibroblast
infect
n
proteinexpress
di
attenu
vaccinia
viru
plate
block
ova
pbstween
incub
sera
serial
dilut
h
room
temperatur
plate
incub
either
peroxidaseconjug
antimous
igg
zyme
san
francisco
ca
igm
iga
southern
biotechnolog
birmingham
al
antibodi
detect
igg
subclass
either
peroxidaseconjug
antimous
igg
igg
igg
zyme
igg
southern
biotechnolog
use
plate
wash
three
time
pbstween
step
antibodi
detect
ophenylenediamin
zyme
absorb
well
read
nm
use
model
micropl
reader
biorad
hercul
ca
standard
igg
detect
serum
obtain
hyperimmun
mous
valu
uml
standard
assay
sarscovspecif
igg
titer
calcul
follow
sarsspecif
igg
titer
uml
unit
valu
obtain
well
coat
virusinfect
cell
lysat
unit
valu
obtain
well
coat
noninfect
cell
lysat
recombin
n
protein
amino
acid
sarscov
biodesign
saco
dilut
lgml
pb
ad
per
well
plate
support
nitrocellulos
filter
millipor
bedford
overnight
incub
plate
wash
pb
three
time
block
overnight
ova
pbstween
erythrocyt
lysi
singl
cell
suspens
bm
suspend
rpmi
supplement
fc
mm
lglutamin
uml
penicillin
lgml
streptomycin
appli
plate
concentr
cell
per
well
h
cultiv
plate
recov
stain
alkalin
phosphataseconjug
antimous
igg
antibodi
southern
biotechnolog
alkalin
phosphatas
activ
visual
use
carbozol
napthol
asmx
phosphatefast
blue
bb
sigma
frequenc
plasma
cell
specif
n
protein
determin
n
proteinco
plate
background
uncoat
plate
subtract
serum
inactiv
incub
min
known
tissu
cultur
infecti
dose
tcid
sarscov
incub
h
presenc
absenc
serum
antibodi
serial
dilut
ad
vero
cell
cultur
grown
confluent
microtit
plate
h
cell
fix
formaldehyd
stain
crystal
violet
visual
cytopath
effect
induc
viru
neutral
antibodi
titer
express
minimum
dilut
number
serum
inhibit
cytopath
effect
purifi
sarscov
virion
lg
fraction
sdspage
reduc
condit
protein
transfer
pvdf
membran
genet
tokyo
japan
react
dilut
sera
obtain
mice
inocul
uvirradi
sarscov
wash
membran
react
hrpconjug
f
fragment
antimous
igg
hl
jackson
immuno
research
west
grove
pa
follow
visual
band
xray
film
kodak
rochest
ny
use
chemiluminesc
regent
amasham
bioscienc
piscataway
nj
poplit
inguin
lymph
node
spleen
harvest
mice
week
boost
vaccin
prepar
singl
cell
suspens
cell
purifi
deplet
igd
igm
cell
use
magnet
cell
sort
system
mac
miltenyi
biotec
bergisch
gladbach
germani
prepar
antigenpres
cell
apc
normal
balbc
mous
splenocyt
deplet
cell
mac
irradi
cgi
purifi
cell
taken
lymph
node
cellswel
cultur
irradi
apc
cellswel
presenc
absenc
uvirradi
purifi
sarscov
virion
lgml
four
day
cultiv
level
cytokin
concentr
cultur
supernat
measur
flow
cytometri
use
mous
cytokin
cytometr
bead
array
kit
becton
dickinson
san
jose
ca
tcell
prolifer
monitor
incorpor
h
thymidin
kbqwell
icn
biomed
costa
mesa
ca
ad
h
prior
cell
harvest
cell
harvest
micropl
bond
gfb
filter
packard
instrument
meriden
ct
incorpor
radioact
count
micropl
scintil
counter
packard
instrument
inocul
uvinactiv
sarscov
result
antigenspecif
igg
respons
probabl
gener
longterm
asc
well
memori
cell
examin
level
antisarscov
respons
mice
inocul
vaccin
candid
three
mice
group
subcutan
inocul
lg
uvinactiv
purifi
sarscov
virionalum
without
alum
virion
inocul
alum
alon
alum
left
untreat
none
control
fig
one
month
inocul
vaccin
mice
elicit
antisar
cov
igg
antibodi
sera
high
level
expect
alum
adjuv
enhanc
level
igg
antibodi
respons
higher
level
without
adjuv
fig
compar
b
mice
boost
week
level
igg
antibodi
group
mice
primari
respons
fig
c
notabl
level
serum
antibodi
induc
singl
inject
virion
even
absenc
alum
adjuv
maintain
least
month
fig
result
suggest
longterm
asc
establish
singl
shot
uvinactiv
virion
administr
upon
restimul
antigen
memori
b
cell
rapidli
differenti
asc
migrat
bone
marrow
establish
longterm
asc
pool
enumer
number
plasma
cell
specif
sarscov
perform
elispot
assay
use
recombin
n
protein
amino
acid
number
coat
antigen
consist
serum
antisar
cov
igg
level
sarsspecif
igg
plasma
cell
maintain
bone
marrow
day
boost
immun
virionalum
fig
contrast
number
spot
control
mice
detect
limit
ie
cell
determin
subclass
serum
antisarscov
igg
antibodi
boost
mice
use
antimous
igg
igg
igg
igg
second
antibodi
elisa
fig
interestingli
level
antisarscov
igg
mice
immun
virionalum
compar
mice
immun
virion
alon
wherea
level
antisarscov
igg
higher
mice
virionalum
mice
virion
alon
contrast
level
igg
igg
antibodi
fairli
low
group
therefor
result
indic
vaccin
combin
inactiv
virion
alum
induc
predominantli
immun
respons
also
measur
serum
immunoglobulin
igg
earli
late
phase
immun
avoid
high
igg
concentr
interf
detect
igm
iga
antibodi
serum
igg
absorb
protein
gconjug
bead
level
antisarscov
igm
antibodi
iggdeplet
sera
obtain
week
prime
detect
limit
likewis
antisarscov
iga
antibodi
iggdeplet
sera
obtain
week
booster
detect
data
shown
whether
immun
sera
possess
neutral
activ
sarscov
crucial
aspect
vaccin
estim
neutral
activ
sera
obtain
week
boost
inocul
tabl
observ
neutral
activ
sarscov
detect
high
level
sera
mice
inocul
virionalum
virion
alon
taken
togeth
result
indic
subcutan
vaccin
uvinactiv
sarscov
virion
abl
elicit
suffici
amount
igg
antibodi
neutral
activ
use
immun
sera
mice
boost
virionalum
week
analyz
specif
serum
igg
western
blot
analysi
see
method
shown
fig
robust
signal
detect
kda
correspond
n
protein
sarscov
predict
genom
size
band
near
kda
appear
correspond
protein
analog
protein
human
coronavirus
known
heavili
glycosyl
detect
kda
kda
respect
result
consist
data
report
recent
xiao
et
al
express
fulllength
glycoprotein
sarscov
strain
cell
show
protein
kda
sd
gel
origin
kda
faint
kda
band
unknown
howev
similar
band
also
detect
fluorogram
use
antin
mab
ohnishi
k
sakaguchi
takasuka
n
et
al
unpublish
data
suggest
relat
n
protein
specif
igg
immun
sera
also
determin
elisa
plate
coat
lysat
cell
infect
either
sor
nexpress
recombin
vaccinia
virus
fig
result
indic
anti
well
antin
protein
igg
antibodi
elicit
virionalum
vaccin
examin
whether
subcutan
vaccin
mice
gain
induc
tcell
respons
sarscov
mice
immun
either
virionalum
virion
alum
via
footpad
cell
mice
enrich
spleen
region
lymph
node
week
booster
immun
cultur
irradi
apc
presenc
absenc
uvinactiv
sarscov
virion
lgml
shown
fig
region
lymph
node
cell
prolifer
vitro
respons
uvinactiv
virion
virionalumimmun
mice
lesser
extent
virionimmun
mice
mice
inocul
virionalum
show
high
basal
level
prolifer
lymph
node
cell
absenc
antigen
much
differ
net
prolif
respons
cell
virion
alum
group
virion
group
hand
splenic
cell
low
level
prolifer
observ
virionalum
group
mice
level
prolifer
cell
howev
viriondos
independ
therefor
result
suggest
subcutan
inject
inactiv
virion
even
without
alum
induc
cell
activ
extent
drain
lymph
node
result
hardli
occur
system
also
measur
level
cytokin
product
supernat
lymph
node
cell
stimul
inactiv
virion
vitro
day
found
inactiv
virion
induc
product
cytokin
ifnc
tnfa
cell
virionalumimmun
mice
dosedepend
manner
fig
likewis
cell
virionimmun
mice
produc
low
yet
signific
level
cytokin
dosedepend
manner
except
contrast
lymph
node
cell
normal
mice
produc
cytokin
respons
virion
suggest
virion
possess
innat
stimul
activ
bacteri
product
lipopolysaccharid
lp
purifi
protein
deriv
mycobacterium
tuberculosi
ppd
taken
togeth
result
suggest
subcutan
vaccin
uvinactiv
sarscov
abl
activ
cell
region
lymph
node
cell
produc
sever
immunoregulatori
cytokin
includ
ifnc
present
result
demonstr
even
singl
subcutan
administr
uvirradi
virion
without
alum
adjuv
induc
high
level
system
antisarscov
antibodi
respons
mice
probabl
follow
gener
longterm
antibodysecret
cell
memori
cell
bone
marrow
consid
polyval
particul
six
mice
examin
detect
neutral
activ
sera
obtain
mice
week
boost
vaccin
subject
sarscov
neutral
activ
assay
describ
method
titer
reciproc
number
minimum
serum
dilut
inhibit
cytopath
effect
structur
hepat
b
viru
surfac
antigenbas
gagbas
ty
viruslik
particl
shown
elicit
humor
well
cellular
immun
respons
particul
probabl
compar
dimens
structur
pathogen
target
uptak
apc
facilit
induct
potent
immun
respons
antibodi
elicit
mice
vaccin
current
protocol
without
adjuv
recogn
n
protein
sarscov
abl
neutral
infect
viru
vero
cell
howev
serum
antisarscov
iga
antibodi
detect
probabl
owe
rout
vaccin
addit
present
vaccin
protocol
caus
cell
respons
region
lymph
node
although
allow
induct
suffici
cellular
immun
respons
system
show
potenti
subcutan
inject
inactiv
virion
alum
util
current
human
vaccin
alum
use
adjuv
vaccin
diphtheria
pertussi
tetanu
vaccin
long
safeti
record
human
use
observ
addit
alum
vaccin
formula
result
larg
augment
serum
igg
product
igg
product
level
igg
alumvaccin
mice
reach
level
similar
found
hyperimmun
mice
subcutan
inject
lg
inactiv
virion
emulsifi
complet
freund
adjuv
follow
consecut
threetim
intraven
booster
lg
virion
alum
known
select
stimul
igg
domin
type
immun
respons
review
activ
complement
alum
could
contribut
type
immun
respons
partli
via
inhibit
product
interestingli
quit
recent
report
demonstr
aluminduc
myeloid
cell
popul
produc
activ
bcell
variou
diseas
associ
anim
coronaviru
infect
clinic
manifest
diseas
correl
protect
immun
studi
extens
anim
coronaviru
infect
review
although
antibodi
cell
may
play
role
exacerb
patholog
anim
coronaviru
infect
humor
cellular
immun
respons
known
contribut
protect
coronaviru
infect
murin
hepat
viru
group
coronaviru
mortal
suscept
mice
partial
prevent
transfer
immun
serum
contain
neutral
antibodi
prior
challeng
recent
zhiyong
et
al
report
murin
acut
infect
model
neutral
antibodi
elicit
vaccin
dna
encod
protect
cellular
compon
vaccin
mice
requir
inhibit
viral
replic
twice
parenter
administr
inactiv
virion
alum
induc
high
level
antibodi
abl
neutral
sarscov
vaccin
protocol
may
certain
effect
protect
human
sarscov
infect
observ
two
success
inocul
inactiv
viru
week
interv
gener
sarscovspecif
cell
cell
restimul
irradi
viru
vitro
respons
low
term
level
prolifer
product
infc
howev
irrespect
vaccin
protocol
without
alum
adjuv
virusprim
cell
vaccin
anim
capabl
produc
high
level
upon
vitro
stimul
compar
report
varieti
vaccin
studi
outlook
seem
compat
idea
present
vaccin
protocol
may
tend
select
tcell
subset
phenotyp
howev
remain
elucid
whether
cell
may
exhibit
serolog
memori
phenotyp
persist
immun
system
vaccin
long
memori
b
cell
may
persist
day
post
vaccin
addit
analysi
need
clarifi
whether
tcell
respons
crucial
factor
longterm
protect
sarscov
infect
effort
develop
sarscov
vaccin
carri
mani
profit
nonprofit
organ
variou
way
exampl
recent
report
combin
adenoviru
vector
express
sarss
n
protein
elicit
neutral
capac
serum
nspecif
tcell
respons
rhesu
macaqu
howev
still
uncertain
whether
immun
compon
sarscov
suffici
viru
protect
sarscov
tend
caus
replic
error
may
allow
viru
escap
hostimmun
respons
result
season
outbreak
point
view
resembl
influenza
viru
influenza
viru
inactiv
ha
vaccin
show
incomplet
protect
certain
efficaci
safeti
record
long
period
time
inde
approach
use
veterinari
field
bovin
coronaviru
canin
coronaviru
advantag
make
whole
kill
virion
prime
candid
sar
vaccin
even
may
best
protect
abil
unfortun
inform
avail
far
immun
correl
protect
human
coronavirus
includ
sarscov
consider
sarscov
transmiss
occur
direct
contact
droplet
fecal
oral
rout
mucos
secretari
iga
lower
respiratori
tract
digest
tract
seem
crucial
import
failur
induc
igatyp
antibodi
current
system
vaccin
method
improv
notabl
iga
antibodi
detect
sera
bronchoalveolar
lavag
fluid
obtain
mice
hyperimmun
uvirradi
viru
data
shown
therefor
nontox
potent
adjuv
becom
avail
human
use
subcutan
inject
inactiv
virion
would
becom
effect
vaccin
method
reduc
number
suscept
peopl
futur
necessari
determin
whether
inactiv
whole
virion
vaccin
possess
protect
abil
sarscov
infect
use
adequ
anim
model
furthermor
whether
alum
addit
augment
protect
effect
period
sarscov
virion
vaccin
address
current
use
inactiv
influenza
viru
whole
virion
vaccin
significantli
effect
without
adjuv
meanwhil
also
need
develop
potent
adjuv
induct
much
stronger
mucos
immun
addit
evalu
avail
method
virion
inactiv
